[{"id":"00f70968-55e5-42f6-a242-04c73add3d0f","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=55a584b1d52a4846a0a5c9aa9d2cc786","created_at":"2026-06-27T02:08:28.982Z","updated_at":"2026-06-27T02:08:28.982Z","phase":"Phase 3","brief_title":"A study on the efficacy and safety of abecilibin in combination with lasoxifene or fulvestrant in patients with ER+, ER2-, ESR1-mutant locally advanced or metastatic breast cancer.","source_id_and_acronym":"CTR20242519","lead_sponsor":"Not applicable / Shanghai Henlius Biotech Co., Ltd. / Catalent Greenville, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" TP53 mutation • HER-2 negative • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HER-2 negative • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • Fablyn (lasofoxifene)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/23/2024","start_date":" 12/23/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"0344272e-c9eb-4787-b248-9a8ab79cded0","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=007493b7c49041b18aa5b7162e1f33af","created_at":"2026-06-27T02:25:00.939Z","updated_at":"2026-06-27T02:25:00.939Z","phase":"Phase 1","brief_title":"Phase I study of AMT-151 in patients with advanced solid tumors","source_id_and_acronym":"CTR20232237","lead_sponsor":"Puzhong Discovery Medical Technology (Shanghai) Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"064a4100-2bbb-4b81-a49f-7a66737513ee","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ea5a76a977fe447fa58c00df33576195","created_at":"2026-06-27T02:18:41.777Z","updated_at":"2026-06-27T02:18:41.777Z","phase":"Phase 1","brief_title":"Phase I clinical study of FZ-AD004 antibody-drug conjugate for injection in patients with advanced solid tumors","source_id_and_acronym":"CTR20231414","lead_sponsor":"Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd.","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FZ-AD004"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"06ce7167-9431-4d8c-8028-ca428e2ebce9","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ddc2986a0c52440dba114692bd3178aa","created_at":"2026-06-27T02:06:32.967Z","updated_at":"2026-06-27T02:06:32.967Z","phase":"Phase 2","brief_title":"An open-label, multicenter phase II clinical trial of A166 for injection for the treatment of HER2-positive unresectable or metastatic breast cancer previously treated with topoisomerase inhibitor antibody-drug conjugates (ADCs).","source_id_and_acronym":"CTR20242261","lead_sponsor":"Sichuan Kelun Biotech Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sertaly (trastuzumab botidotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/20/2024","start_date":" 09/20/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"080bc5a9-ac50-4ae7-a5d7-f1379fd206e5","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=3d99cf1005c642ea86c41aff2eb52314","created_at":"2026-06-27T01:56:51.700Z","updated_at":"2026-06-27T01:56:51.700Z","phase":"Phase 3","brief_title":"A Phase III clinical trial evaluating leuprorelin injection emulsion for the treatment of premenopausal breast cancer.","source_id_and_acronym":"CTR20240920","lead_sponsor":"Yida Biotechnology Co., Ltd. / Changchun Jinsai Pharmaceutical Co., Ltd. / Fareva PAU","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/09/2024","start_date":" 09/09/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"0e405919-15e3-420f-82b4-cf7afb1e2197","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=2e3c992c743e438387b39f762287202a","created_at":"2026-06-27T01:56:49.015Z","updated_at":"2026-06-27T01:56:49.015Z","phase":"Phase 1","brief_title":"BAT-8008-1308-001-CR","source_id_and_acronym":"CTR20240914","lead_sponsor":"Bio-Thera Solutions, Ltd.","biomarkers":" PD-L1 • TACSTD2","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAT8008 • BAT1308"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 04/23/2024","start_date":" 04/23/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"16ff3914-98c8-4944-98fc-1f090a82b038","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=9564fbda553c43d5877b5205622d3371","created_at":"2026-06-27T02:27:53.714Z","updated_at":"2026-06-27T02:27:53.714Z","phase":"Phase 3","brief_title":"A phase III, randomized, open-label study (VERITAC-3) comparing ARV-471 (PF-07850327) plus palbociclib versus letrozole plus palbociclib in patients with ER(+)/HER2 (-) advanced breast cancer.","source_id_and_acronym":"CTR20232668","lead_sponsor":"Pfizer Inc. / Hovione FarmaCiencia SA","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • Veppanu (vepdegestrant)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"22017b06-ce77-4d93-aa35-2e39b02c8318","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=41d2d78a9b31487d943cbb3e24dba7b3","created_at":"2026-06-27T02:14:28.876Z","updated_at":"2026-06-27T02:14:28.876Z","phase":"Phase 2","brief_title":"JK1201I Phase II Clinical Study for the Treatment of HER2-Negative Breast Cancer with Brain Metastases","source_id_and_acronym":"CTR20243210","lead_sponsor":"Tianjin Jiankai Technology Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 negative • HER-2 expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated irinotecan (SSS22)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/14/2024","start_date":" 11/14/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"25596c51-48fd-4ead-8589-2ac5236de783","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=fe4650d98b764b4a9e2beaa22605d9dd","created_at":"2026-06-27T01:55:52.756Z","updated_at":"2026-06-27T01:55:52.756Z","phase":"Phase 2/3","brief_title":"Dosage optimization and phase 3 controlled study of R-DXd versus investigator-selected chemotherapy in platinum-resistant ovarian cancer","source_id_and_acronym":"CTR20240778","lead_sponsor":"Daiichi Sankyo, Inc. / Daiichi Sankyo (China) Investment Co., Ltd.","biomarkers":" FOLR1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["FOLR1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e raludotatug deruxtecan (DS-6000)"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 08/05/2024","start_date":" 08/05/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"278a143a-c835-4143-b593-846029bf6335","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=a38ec57ecde24ed0a035822ceb4422a1","created_at":"2026-06-27T01:58:14.543Z","updated_at":"2026-06-27T01:58:14.543Z","phase":"Phase 1/2","brief_title":"A phase Ib/IIa clinical study of BAT 8010 for injection in combination with BAT 1006 for the treatment of locally advanced or metastatic solid tumors.","source_id_and_acronym":"CTR20241120","lead_sponsor":"Bio-Thera Solutions, Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAT1006 • BAT8010"],"overall_status":"Recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 05/22/2024","start_date":" 05/22/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"3c34ccf1-02f5-433e-8ec1-6fe6e17d5691","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=cd9d33c1eafc47c3bb81428c1fee93bf","created_at":"2026-06-27T02:18:58.053Z","updated_at":"2026-06-27T02:18:58.053Z","phase":"Phase 1","brief_title":"A Phase I/II clinical study of the safety, tolerability, pharmacokinetics, and preliminary efficacy of CBP-1019 for injection in patients with advanced malignant solid tumors.","source_id_and_acronym":"CTR20231450","lead_sponsor":"Tongyi Pharmaceutical (Hefei) Co., Ltd.","biomarkers":" FOLR1 • TRPV6","pipe":"","alterations":" ","tags":["FOLR1 • TRPV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CBP-1019"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/29/2023","start_date":" 08/29/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"3cc93195-b6fe-4f60-9e04-428bba1b12fd","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=c40c4978d3a34d22bbe9b409ecf4f175","created_at":"2026-06-27T02:25:38.477Z","updated_at":"2026-06-27T02:25:38.477Z","phase":"Phase 1","brief_title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, and initial efficacy of AND019 in patients with advanced/metastatic ER+/HER2- breast cancer: an open-label, dose-escalation, and dose-expansion phase I clinical study.","source_id_and_acronym":"CTR20232325","lead_sponsor":"Hangzhou Andao Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AND019"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/12/2024","start_date":" 01/12/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"40a41a86-981f-4aee-9e1b-b2e3904995d0","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=a457c3f39bd14581ad15a532abd597bb","created_at":"2026-06-27T02:24:53.275Z","updated_at":"2026-06-27T02:24:53.275Z","phase":"Phase 2","brief_title":"Phase II clinical trial of vedicetumab in combination with toripalimab as neoadjuvant therapy for HR-positive, HER2-low-expressing breast cancer patients.","source_id_and_acronym":"CTR20232219","lead_sponsor":"Rongchang Biopharmaceutical (Yantai) Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • cyclophosphamide • epirubicin • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 04/29/2024","start_date":" 04/29/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"41c9c14c-8a8f-4d94-9c71-faff37a62979","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=5c7528c3c87c42dab7c744696c45ab97","created_at":"2026-06-27T01:59:38.345Z","updated_at":"2026-06-27T01:59:38.345Z","phase":"Phase 2","brief_title":"Phase II clinical trial of FDA022-BB05 in patients with advanced solid tumors","source_id_and_acronym":"CTR20241323","lead_sponsor":"Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression • HER-2 underexpression"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/21/2024","start_date":" 06/21/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"46ea5fc9-4980-4103-9d13-7ed486d2ad5d","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=c5048f51b8ae4bdc8be595186d5aca4c","created_at":"2026-06-27T02:00:53.247Z","updated_at":"2026-06-27T02:00:53.247Z","phase":"Phase 2","brief_title":"A phase IIa clinical trial evaluating the safety and efficacy of ALMB-0168 in patients with advanced solid tumor bone metastases.","source_id_and_acronym":"CTR20241498","lead_sponsor":"Shanghai Enlem Biotechnology Co., Ltd.","biomarkers":" PIK3CA • BRCA1 • BRCA2","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HR positive","tags":["PIK3CA • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HR positive"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 144","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"4c8733d8-4b89-44ae-8794-573514e2b06a","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=98d9067ee1e94dd5bcd9605bd1563dab","created_at":"2026-06-27T02:23:35.871Z","updated_at":"2026-06-27T02:23:35.871Z","phase":"Phase 1","brief_title":"Safety and efficacy study of C-13-60 in CEA-positive advanced malignant solid tumors","source_id_and_acronym":"CTR20232041","lead_sponsor":"Chongqing Precision Biotechnology Co., Ltd.","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • ALK positive • EGFR T790M • ALK fusion • EGFR positive","tags":["PD-L1 • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • ALK positive • EGFR T790M • ALK fusion • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/23/2023","start_date":" 10/23/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"4e10e10a-f5e1-4c5b-8c7d-410365daf5ab","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=8e7688ee048b44d5aa645ae8e513d8ae","created_at":"2026-06-27T02:20:10.199Z","updated_at":"2026-06-27T02:20:10.199Z","phase":"Phase 3","brief_title":"Studies of Camizestrant in ER+/HER2- early breast cancer after at least 2 years of standard adjuvant endocrine therapy","source_id_and_acronym":"CTR20231633","lead_sponsor":"AstraZeneca AB / AstraZeneca Investment (China) Co., Ltd. / Patheon Manufacturing Services LLC","biomarkers":" HER-2 • ER • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • ER positive • BRCA1 mutation • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • ER positive • BRCA1 mutation • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • exemestane • Etcamah (camizestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 645","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"4fa116ed-8368-4785-b0ec-3919a63a256e","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=d7a91b8bb73a4b86a683e6a42d7a9349","created_at":"2026-06-27T02:29:03.775Z","updated_at":"2026-06-27T02:29:03.775Z","phase":"Phase 1","brief_title":"A Phase I clinical study evaluating BRY812 for injection as monotherapy in patients with advanced malignant tumors.","source_id_and_acronym":"CTR20232761","lead_sponsor":"Zhejiang Borui Biopharmaceutical Co., Ltd. / Hisun Biopharmaceutical Co., Ltd.","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e laventatug tivedotin (BRY812)"],"overall_status":"Recruiting","enrollment":" Enrollment 164","initiation":"Initiation: 10/17/2023","start_date":" 10/17/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"5de90bf1-134d-4a4b-9f9c-64ebd9a46868","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=1fc9aab40a094e6bb143d6c4ea1be209","created_at":"2026-06-27T02:03:16.250Z","updated_at":"2026-06-27T02:03:16.250Z","phase":"Phase 3","brief_title":"A phase III clinical trial of PM8002 or placebo in combination with chemotherapy as first-line treatment for triple-negative breast cancer.","source_id_and_acronym":"CTR20241802","lead_sponsor":"Promis Biotechnology (Zhuhai) Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • pumitamig (BNT327)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"5f05857a-a4cd-4e05-8140-b7b035c3f8a3","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=164d7eaa2e4f4a8ba95eb5ae31f09afa","created_at":"2026-06-27T02:30:02.665Z","updated_at":"2026-06-27T02:30:02.665Z","phase":"Phase 2","brief_title":"A phase II clinical trial of SI-B003 monotherapy and BL-B01D1+SI-B003 dual therapy for patients with unresectable locally advanced or recurrent metastatic HER2-negative breast cancer (currently, the monotherapy portion is being conducted first).","source_id_and_acronym":"CTR20232905","lead_sponsor":"Chengdu Bailidote Biopharmaceutical Co., Ltd. / Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 12/20/2023","start_date":" 12/20/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"6560b97b-3122-44cd-a865-71153299925a","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=03bae657cb794093a19e6e76a059f51f","created_at":"2026-06-27T01:56:19.186Z","updated_at":"2026-06-27T01:56:19.186Z","phase":"Phase 3","brief_title":"A phase III randomized study evaluating the use of Dato-DXd and durvalumab injections before and after surgery in adult breast cancer patients.","source_id_and_acronym":"CTR20240839","lead_sponsor":"Daiichi Sankyo, Inc. / AstraZeneca Investment (China) Co., Ltd. / Baxter Oncology GmbH","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • epirubicin • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 04/18/2024","start_date":" 04/18/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"6addb0b7-d0e8-4526-963c-a232f5296048","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ca06a0f3f7294969a8a0a16e23fe9ee9","created_at":"2026-06-27T02:00:23.336Z","updated_at":"2026-06-27T02:00:23.336Z","phase":"Phase 1","brief_title":"Phase I clinical trial of JSKN016 for the treatment of advanced solid tumors","source_id_and_acronym":"CTR20241426","lead_sponsor":"Jiangsu Kangning Jierui Biopharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"6d390b03-4083-445a-9c24-654750ae9491","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=e8f9175505644e32b48cee6d2d8656ab","created_at":"2026-06-27T01:59:14.000Z","updated_at":"2026-06-27T01:59:14.000Z","phase":"Phase 1","brief_title":"A Phase I clinical study evaluating IUAb190708 injection in subjects with advanced or recurrent solid tumors.","source_id_and_acronym":"CTR20241263","lead_sponsor":"Innobio Biopharmaceuticals (Suzhou) Co., Ltd.","biomarkers":" PD-L1 • MSI • PD-1","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • MSI • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/18/2024","start_date":" 06/18/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"6e23f265-ee96-4704-9ded-2bd6b546d87d","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=84f1c2152d5b484fb86adb0af9e92b94","created_at":"2026-06-27T02:24:27.794Z","updated_at":"2026-06-27T02:24:27.794Z","phase":"Phase 1","brief_title":"A phase I/IIA dose-escalation and expansion study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PF-07248144 in subjects with advanced or metastatic solid tumors.","source_id_and_acronym":"CTR20232154","lead_sponsor":"Pfizer Inc. / Pfizer Investment Co., Ltd.","biomarkers":" HER-2 • ER • CDKN2A","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Veppanu (vepdegestrant) • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/07/2023","start_date":" 08/07/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"}]